Share

Pioneering the Next Generation of Treatment Solutions

We support innovation across the continuum of care, to help to develop new technologies, treatments and vaccines.
Innovation portfolio grows with collaborations advancing potential treatments for obesity and related complications such as diabetes and non-alcoholic steatohepatitis (NASH), novel therapeutics for rheumatoid arthritis; 3-D printing of custom health solutions.
Based on final Phase 1 data published in JAMA, prime-boost Ebola vaccine regimen induced antibody response that persisted in 100 percent of healthy volunteers to at least 1 year following vaccination. Vaccine development partners include U.S. National Institutes of Health, Europe’s Innovative Medicines Initiative, Bavarian Nordic, London School of Hygiene &Tropical Medicine, University of Oxford, Inserm and BARDA.
Competition Part of Company’s Eighty-Five Year Commitment to Supporting Entrepreneurs, Science Education Opportunities, and Health Systems Across the Continent
From helping stop the spread of disease in public bathrooms in Uganda to supporting local farmers in Liberia, these savvy troubleshooters have devised simple healthcare solutions with serious impact.
Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), announced today that the U.S. Food and Drug Administration (FDA) has approved VERMOXTM CHEWABLE (mebendazole chewable 500mg tablets) for the treatment of patients one year of age and older with gastrointestinal infections caused by Ascaris lumbricoides (roundworm) and Trichuris trichiura (whipworm).
Johnson & Johnson Global Public Health partner, the International Partnership for Microbicides, announced that The New England Journal of Medicine has published results from The Ring Study, a Phase III clinical trial of IPM’s vaginal ring to prevent HIV.
Johnson & Johnson Chief Scientific Officer, Dr. Paul Stoffels, shares his perspective on the future of HIV with Business Insider.
Our hope, our dream is to develop an HIV vaccine that has the potential to prevent HIV and liberate communities from HIV for good. Watch this video to learn more.
The U.S. Food and Drug Administration granted Priority Review designation to Janssen’s new drug application for a chewable tablet formulation of mebendazole, which treats and prevents soil-transmitted helminthiasis, also known as intestinal worm infestations.
From launching initiatives around the globe to help reduce the burden of HIV in women and children, to developing six transformational HIV medicines, we are committed to helping eliminate HIV.
While significant progress has been made since the 2000 International AIDS Conference in Durban, South Africa, there is still work to be done, according to this AIDS 2016 update from BioWorld.
We continue to seek strategic partnerships to help make HIV history, whether it’s through collaborations between industry and non-profit organizations, public-private partnerships, or some combination of both.
Phase IIb data presented at the Conference on Retroviruses and Opportunistic Infections 2016 demonstrated comparable antiviral activity between two injectable HIV medicines given together and the 3-drug oral antiretroviral therapy.
The International Partnership for Microbicides (IPM) announced results of The Ring Study and ASPIRE, demonstrating that a monthly vaginal ring containing Janssen’s antiretroviral drug, dapivirine, can safely help prevent HIV-1 infection in women.
Learn more about the progress Johnson & Johnson made with its HIV efforts in 2015.
The New York Times reported on the results of The Ring Study and ASPIRE demonstrating that a vaginal ring containing Janssen’s antiretroviral drug helped lower HIV rates in African women.
Janssen and ViiV Healthcare formalized their collaboration on phase III development and commercialization of a two drug regimen for the treatment of HIV.
Empowering young women and adolescent girls, one of the populations at greatest risk in sub-Saharan Africa, to live healthy and productive lives is a critical need as we face this urgent global health problem.
Janssen announced topline phase IIb data showing comparable efficacy between two injectable HIV medicines given together and the 3-drug oral antiretroviral therapy.
A reflection on the progress that has been made and the challenges that still remain to make HIV history.
In this Devex blog, Johnson & Johnson leadership discusses the potential impact of an HIV vaccine.
Janssen expanded policy aimed at enhancing access to its HIV medicine, darunavir, to children in 128 low- and middle-income countries.
Executives from the International Partnership for Microbicides (IPM) and Johnson & Johnson discuss a new agreement to help ensure women have the tools to protect themselves from HIV infection in GlobalPost.com.
Janssen announced an expanded collaboration with the International Partnership for Microbicides (IPM) to develop, commercialize and deliver its HIV medicine, dapivirine, to women in lower income communities.
Learn about Johnson & Johnson’s commitment to improve the health of women and children in five key areas.
Janssen Pharmaceuticals, Inc. received the prestigious International Prix Galien, recognizing excellence in scientific innovation to improve human health.
Economic Times reported on the memorandum of understanding that Johnson & Johnson has entered into with the Telangana government in India to work together towards making the state TB-free.
Johnson & Johnson was named to Fortune’s 2016 Change the World list for its efforts to combat multi drug-resistant tuberculosis with the first new treatment for TB in more than 40 years.
The Union and its affiliate Vital Strategies, announced that the STREAM Stage 2 clinical study, evaluating shorter and simpler MDR-TB treatment regimens with SIRTURO®, has started enrolling patients at a clinical trial site in Mongolia.
Janssen India leadership discusses new initiative to combat MDR-TB in India with The Hindu Business Line.
Times of India reports on launch of a new program to help combat MDR-TB and XDR-TB in India.
Janssen announced a collaboration with the International Union Against Tuberculosis and Lung Disease (The Union) to include SIRTURO® (bedaquiline) in an ongoing study that explores a standardized treatment regimen for patients with MDR-TB.
Janssen provided a grant to Harvard Medical School to develop a two-year research, policy and advocacy program to improve access to TB diagnosis and treatment with a focus on children.
Janssen announced that SIRTURO® (bedaquiline) was granted conditional approval in the European Union for use in a combination treatment regimen for pulmonary MDR-TB.
Learn more about our first-in-class drug indicated for MDR-TB.
Janssen announced the FDA granted accelerated approval to SIRTURO® (bedaquiline) as part of a combination therapy for use in adult pulmonary MDR-TB.
Janssen announced the FDA granted Priority Review to SIRTURO® (bedaquiline) to treat adult pulmonary MDR-TB as part of combination therapy.
VERMOX™ CHEWABLE treats patients one year of age and older with gastrointestinal infections caused by roundworm and whipworm infections.
If the World Health Organization grants the listing, this will accelerate the global availability of Janssen’s investigational Ebola prime-boost vaccine regimen if another Ebola crisis occurs.
Janssen announced the start of a first-in-human Phase 1 clinical study for its multivalent vaccine regimen to protect against Ebola, Sudan and Marburg viruses.
Esketamine, Janssen’s investigational antidepressant medication for major depressive disorder with imminent risk of suicide, received FDA Breakthrough Therapy Designation.
The U.S. Food and Drug Administration granted Priority Review designation to Janssen’s new drug application for a chewable tablet formulation of mebendazole, which treats and prevents soil-transmitted helminthiasis, also known as intestinal worm infestations.
The Idylla™ Ebola Virus Triage Test, jointly developed by Janssen Diagnostics, a division of Janssen Pharmaceutica, Biocartis NV (Biocartis), and the Belgium Institute of Tropical Medicine, was granted Emergency Use Authorization by the U.S. Food and Drug
Janssen announced the submission of a New Drug Application to the FDA for a 500mg mebendazole chewable tablet to treat adults and children aged one year or older with intestinal worm infections.
The first clinical data for an Ebola prime-boost vaccine regimen being developed by the Janssen Pharmaceutical Companies of Johnson & Johnson have been published in JAMA: The Journal of the American Medical Association.
Johnson & Johnson leadership discusses the first clinical results for a prime-boost vaccine regimen study conducted in the UK.
Economic Times interviews Johnson & Johnson leadership about efforts to develop a vaccine to combat Zika virus
Our Global Public Health strategy aims to build on our legacy by designing and delivering innovative, integrated solutions that demonstrate measurable long-term health outcomes.
The American Pharmacists Association reports on a research collaboration between Janssen and the UC San Diego Skaggs School of Pharmacy to treat Chagas disease.
Peter Piot, who co-discovered the Ebola virus in 1976, and Johnson & Johnson leadership discuss the urgent need to focus resources on finding vaccines and therapies to help fight Ebola with The Guardian.
A reflection on an Operation Smile mission in Paraguay and how the lives of children are being transformed through reconstructive surgery for cleft lip, cleft palate and other facial deformities.
Johnson & Johnson Global Public Health partner, the International Partnership for Microbicides, announced that The New England Journal of Medicine has published results from The Ring Study, a Phase III clinical trial of IPM’s vaginal ring to prevent HIV.a
Economic Times reported on the memorandum of understanding that Johnson & Johnson has entered into with the Telangana government in India to work together towards making the state TB-free.
Bloomberg reports on the positive immune response demonstrated in a Phase 1 clinical study of our Ebola prime-boost vaccine regimen being developed with help from global partners.
This site uses cookies as described in our Cookie Policy. Please click the "Accept" button or continue to use our site if you agree to our use of cookies.
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Continue